Business
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer - 62% of patients saw a reduction in CA-125 levels
About this update from Sutro Biopharma, Inc.
[{"type":"text","content":"Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer\n - 62% of patients saw a reduction in CA-125 levels of 50% or more or a normalization of CA-125 levels\n - 35% of patients who were evaluable for progression have stayed on study for longer than 24 weeks; 11 patients at 5.2 mpk or higher are continuing study and have not yet reached 24 weeks\n - 75% of patients have initial post-baseline scans showing stable disease or a partial response\n - 100% of evaluable patients who had a CA-125 reduction of 50% or more or normalization achieved stable disease (confirmed or unconfirmed) or a partial response and are still on study\n - Generally well-tolerated in this heavily pre-treated patient population - 89% of adverse events were grade 1 or 2\n - Investor conference call and webcast will be held at 8 a.m. EDT summarizing data through April 20, 2020; AACR virtual poster presentation summarizing patient data through April 1, 2020, available at 9 a.m. EDT\n\n\nSOUTH SAN FRANCISCO, Calif., April 27, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced updated interim data regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer from its on-going Phase 1 clinical trial (dose escalation phase) evaluating its folate receptor alpha (FolRα) antibody drug-conjugate (ADC) STRO-002. Sutro will host a conference call and live audio webcast on Monday, April 27, at 8 a.m. EDT to discuss the STRO-002 data.\n\"We designed STRO-002 to have a wider therapeutic window, with the potential for improved tumor control and better patient tolerability, than other FolRα targeted therapies,\" said Bill Newell, CEO of Sutro Biopharma. \"The data we present today from this all-comers trial suggest that our optimally designed ADC can achieve these objectives. In 75% (15 of 20) of ovarian cancer patients at STRO-002 dose levels of 2.9 milligrams per kilogram (mpk) or higher, we saw in the initial post-baseline scans one partial response and 14 stable disease. This level of tumor control is typically very difficult to achieve in these patients who have...